Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns.

Five years later, Noah is a healthy third grader who will turn 9 in July, and the biotech business his dad launched, Luminoah, is also thriving. Piper, who lives in Charlottesville with his family, ...

In December 2024, the Shanghai-based biotech caught the eye of Candid Therapeutics, with the two inking a research deal for novel T-cell engager candidates for various autoimmune indications.

Biotech uses fermentation to produce milk proteins without cows. Your friend's email. Your email. I would like to subscribe to Science X Newsletter. Learn more. Your name. Note.

The changes will extend the biotech’s cash runway into 2027, compared to late 2026 under the previous plan. Rocket’s PKP2 and BAG3 programs are on track and unaffected by the clinical hold ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Biotechnology companies have been a cornerstone of the pharmaceutical industry since the mid-1990s. Today, many of these firms have matured into profitable companies. We divide biotechs into three ...

Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation’s pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for ...

Burning Rock Biotech Limited, specializing in next-generation sequencing for precision oncology, reported its financial results for Q1 2025, showing revenues of RMB133.1 million ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: CRISPR Therapeutics (CRSP-0.41%) and Regeneron Pharmaceuticals (REGN-0.75%).

Today's biotech news includes KJ's homecoming after groundbreaking CRISPR therapy, Vinay Prasad on rare diseases, and more. Skip to Main Content Manage alerts for this article ...